Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.

British journal of cancer - 1 Feb 2021

White Michael G, Schulte Jefree J, Xue Lai, Berger Yaniv, Schuitevoerder Darryl, Vining Charles C, Kindler Hedy L, Husain Aliya, Turaga Kiran K, Eng Oliver S

Abstract excerpt

Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune checkpoint inhibition are yet to be defined. Here, we examine levels of PD-L1 expression in MPM patients treated with systemic and/or intraperitoneal chemotherapy using tissue from patient tumour biopsies or resections at multiple time points. We found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mesothelioma, Malignant

Share to Neoplasm Proteins

Share to Pemetrexed

Share to Peritoneal Neoplasms

Share to Platinum Compounds

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 33100328
DOI: 10.1038/s41416-020-01130-x
PMCID: PMC7851380

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.PMID 33100328Read ↗

Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular LandscapeSemantic proximity Read ↗

Immune Microenvironment and Genetics in Malignant Pleural MesotheliomaSemantic proximity Read ↗

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaSemantic proximity Read ↗

Molecular Characterization of Peritoneal MesotheliomasSemantic proximity Read ↗

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to TherapySemantic proximity Read ↗

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue TypesSemantic proximity Read ↗

Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.Semantic proximity Read ↗

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Semantic proximity Read ↗

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumorsSemantic proximity Read ↗

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Recent Findings in the Regulation of Programmed Death Ligand 1 ExpressionSemantic proximity Read ↗

Comprehensive immunoproteogenomic analyses of malignant pleural mesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.